Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06954129 · ClinicalTrials.gov registry record · Phase 4
A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients
A Phase 4 study of Acute Kidney Injury, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 750
- Enrollment target
- 1
- Study location
NCT06954129: Recruiting Phase 4 study of Acute Kidney Injury, sponsored by University of Pennsylvania.
NCT06954129 is a Phase 4 study of Acute Kidney Injury that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 750 participants, below the 2,321-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06954129, a Phase 4 study of Acute Kidney Injury, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
Hospitalized patients with suspected or confirmed infection are commonly treated with vancomycin (VN) in combination with either piperacillin-tazobactam (PT) or cefepime (CP). Although these regimens have similar effectiveness, recent observational evidence suggests they may differ in terms of the risk for acute kidney injury (AKI). Interpretation of existing evidence is complicated by the limitations of creatinine, the standard biomarker used to monitor kidney function, which has poor sensitivity and specificity for drug induced AKI. To address this important knowledge gap, the investigators propose to conduct a pragmatic, open-label, non-inferiority trial that will examine the comparative risk of AKI between these standard-of-care antibiotic combinations using sensitive and specific markers of drug-induced AKI. We hypothesize that the regimen of VN in combination with PT (VN+PT) is noninferior to the regimen of VN in combination with CP (VN+CP) in terms of AKI risk.
Primary Outcome
Change in serum cystatin c concentration through Day 5 after antibiotic initiation.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Piperacillin-tazobactam
- DRUG Cefepime
Study Locations (1)
Pennsylvania
- University of Pennsylvania Health System - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2029-07 |
| Phase | Phase 4 |
What NCT06954129 shows while recruiting
NCT06954129 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 2,321-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 3 interventions - of which Vancomycin is the first listed.
NCT06954129 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06954129 about?
NCT06954129 is a clinical study titled "A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients". Hospitalized patients with suspected or confirmed infection are commonly treated with vancomycin (VN) in combination with either piperacillin-tazobactam (PT) or cefepime (CP). Although these regimens have similar effectiveness, recent observational evidence suggests they may differ in terms of the r...
What is the current status of trial NCT06954129?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 750 participants. The study started on 2026-01-28. Estimated completion is 2029-07.
What conditions does trial NCT06954129 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT06954129?
The interventions under investigation include: Vancomycin (DRUG), Piperacillin-tazobactam (DRUG), Cefepime (DRUG).
Who is sponsoring clinical trial NCT06954129?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06954129 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06954129's enrollment target sits among peer trials
750 17th of 74 higher than 58 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery
RECRUITING · Phase 4
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI